Abstracts tagged "Spondylarthritis"

Abstract Number: 725 • 2016 ACR/ARHP Annual Meeting
Long-Term Anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in the Sacroiliac Joints in Patients with Non-Radiographic Axial Spa: Six-Year Results of the Esther Trial
Valeria Rios Rodriguez¹, Joachim Sieper¹, Kay-Geert Hermann², Hildrun Haibel¹, Christian Althoff², Beate Buß¹, Olaf Behmer³ and Denis Poddubnyy¹, ¹Rheumatology, Charité Universitätmeidzin Berlin, Berlin, Germany, ²Radiology, Charité Universitätmeidzin Berlin, Berlin, Germany, ³Pfizer Pharma, Berlin, Germany
Background/Purpose: Data from observational studies suggests a 10-12% biannual rate of progression from non-radiographic axial SpA (nr-axSpA) to ankylosing spondylitis (AS)1 in patients not treated…
Abstract Number: 2696 • 2016 ACR/ARHP Annual Meeting
Identification of a Potential Commensal Immunologic Target in Enthesitis-Related Arthritis
Matthew L. Stoll¹, Lennard W. Duck², Randy Q. Cron³ and Charles O. Elson⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁴Dept of Medicine, University of Alabama at Birmingham, Birmingham, AL
Identification of a Potential Commensal Immunologic Target in Enthesitis-related Arthritis Background/Purpose: Research in inflammatory bowel disease (IBD) has identified commensal organisms that stimulate humoral and…
Abstract Number: 3039 • 2016 ACR/ARHP Annual Meeting
Anti-IL-17A, but Not Anti-TNF, Can Halt Pathological New Bone Formation in Experimental Spondyloarthritis
Melissa van Tok¹, Leonie van Duivenvoorde¹, Ina Kramer², Peter Ingold², Veronique Knaup¹, Joel Taurog³, Frank Kolbinger⁴ and Dominique Baeten⁵, ¹Academic Medical Center, Amsterdam, Netherlands, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland, ⁵Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands
Background/Purpose: Secukinumab, a monocloncal antibody to IL-17A, suppresses signs and symptoms as well as inflammation in ankylosing spondylitis and psoriatic arthritis, and inhibits bone and…
Abstract Number: 684 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups
Pinar Cetin¹, Gercek Can¹, Gokce Kenar¹, Handan Yarkan¹, Berrin Zengin¹, Ismail Sari¹, Merih Birlik¹, Fatos Onen¹ and Nurullah Akkoc², ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey
Background/Purpose: The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being. A few studies have assessed…
Abstract Number: 2842 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Justine Corli¹, Rene-Marc Flipo¹, Peggy Philippe², Anne Bera-Louville², Cecile Wibaux² and Julien Paccou², ¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ²Hopital R Salengro CHRU, Lille, France
Background/Purpose: Several studies have demonstrated that Tumor Necrosis Factor Inhibitors (TNFi) are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). However, few investigations have directly compared ankylosing…
Abstract Number: 2875 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Fabiola Atzeni¹, Antonio Carletto², Marco Sebastiani³, Valentina Panetta⁴, Fausto Salaffi⁵, Florenzo Iannone⁶, Elisa Gremese⁷, Marcello Govoni⁸, Antonio Marchesoni⁹, Roberto Gorla¹⁰, Roberta Ramonda¹¹, Pier Carlo Sarzi-Puttini¹², Gianfranco Ferraccioli⁷, Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy, ³SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ⁴L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁵Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁷Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁸Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ⁹Rheumatology Unit, Orthopedic Institute G. Pini, Milano, Italy, ¹⁰Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ¹¹Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ¹²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: The use of TNF inhibitors (TNFIs) has led to efficient control of the signs and symptoms of SpA and rheumatoid arthritis (RA), and significantly…
Abstract Number: 2557 • 2014 ACR/ARHP Annual Meeting
Are We over-Treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime Dougados⁵ and Laure Gossec⁶, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), and even in early forms, patients symptoms may lead to…
Abstract Number: 2573 • 2014 ACR/ARHP Annual Meeting
Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Uta Kiltz¹, Mickaël Hiligsmann², D van der Heijde³, Juergen Braun¹, Alarcos Cieza⁴, Walter P. Maksymowych⁵, William Taylor⁶ and Annelies Boonen⁷, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Psychology, University Southampton, Southampton, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose The ASAS Health Index (ASAS HI) is a disease-specific questionnaire aiming at measurement of health in patients with spondyloarthritis (SpA) which has been developed…
Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Jacqueline E. Paramarta¹, Maureen C. Turina¹, Tanja F. Heijda², Iris C. Blijdorp³, Troy Noordenbos¹, Nataliya Yeremenko² and Dominique L. Baeten⁴, ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…
Abstract Number: 541 • 2014 ACR/ARHP Annual Meeting
Collagen II Neo-Epitopes in Spondyloarthritis.
Heidi Lausten Munk¹, Natasja Staehr Gudmann², Anne Friesgaard Christensen³, Leif Ejstrup⁴, Grith Lykke Sørensen⁵, Anne Gitte Loft³, Anne C. Bay-Jensen², Anne Sofie Siebuhr² and Peter Junker¹, ¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ⁴Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, ⁵Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark
Background/Purpose Spondyloarthritis (SpA) is characterized by aseptic inflammation of the axial skeleton which may ultimately lead to irreversible deformities due to bony ankylosis. Occasionally, peripheral…
Abstract Number: 144 • 2014 ACR/ARHP Annual Meeting
Sonographic Differentiation of Heel Pain: Focal Degenerative Versus Systemic Inflammatory Enthesitis
Patrick Hook¹, Diana Vradii², Maureen Dubreuil^3,4, Hau Pham⁵ and Eugene Y. Kissin¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Mid Coast Hospital Medical Center, Brunswick, ME, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Podiatry, Boston University Medical Center, Boston, MA
Background/Purpose: Plantar fasciitis and Achilles tendonitis are commonly encountered in a rheumatologic practice due to either degenerative (DG) or systemic inflammatory conditions (SYS). While…
Abstract Number: 3008 • 2014 ACR/ARHP Annual Meeting
High Prevalence of Subclinical Ultrasonographic Enthesopathy and Synovitis in Patients with Inflammatory Bowel Disease without Clinical Signs or Symptoms of Spondyloarthritis
Esther Vicente¹, Silvia Pérez-Esteban², María Chaparro³, Francisco Rodríguez-Salvanés⁴, Lorena Vega⁴, Santos Castañeda¹ and Javier P Gisbert⁵, ¹Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ²Rheumatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Gastroenterology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Epidemiologic Research Unit, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁵Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose Musculoskeletal manifestations as peripheral arthritis, axial disease and enthesitis are present in 10-62% of Inflammatory Bowel Disease (IBD) patients. Ultrasonography is more sensitive than…
Abstract Number: 2983 • 2014 ACR/ARHP Annual Meeting
Infliximab Added to Naproxen Does Not Increase Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints and of the Spine As Compared to Naproxen Alone in Early Axial Spondyloarthritis
Denis Poddubnyy and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Fatty lesions of the bone marrow in the axial skeleton (sacroiliac joints – SIJ, and spine) on magnetic resonance imaging (MRI) are considered nowadays…
Abstract Number: 2596 • 2014 ACR/ARHP Annual Meeting
Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort
Pilar del Río-Martínez¹, Victoria Navarro-Compán², Concepción Castillo-Gallego³, M. Carmen Castro⁴, Eduardo Collantes-Estévez⁴ and Eugenio De Miguel³, ¹Rheumatology,, Rheumatologist, Zaragoza, Spain, ²Rheumatology, Rheumatologist, Madrid, Spain, ³Rheumatology,, Rheumatologist, Madrid, Spain, ⁴Rheumatology, Rheumatologist, Córdoba, Spain

Background/Purpose: Based on the predominant manifestation of the disease, the ASAS classification criteria for spondyloarthritis (SpA) distinguish two clinical forms: •Axial SpA, including non-radiographic SpA…
Abstract Number: 2593 • 2014 ACR/ARHP Annual Meeting
Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort
Denis Poddubnyy¹, Hildrun Haibel¹, Jürgen Braun², Martin Rudwaleit¹ and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose In cross-sectional studies it has been demonstrated that non-radiographic axial spondyloarthritis (nr-axSpA) does not differ from ankylosing spondylitis (AS) with respect to clinical signs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].